Novartis E-Trial Program Will Help Reduce Clinical Trial Personnel By 25%
Executive Summary
Novartis' productivity improvements through electronic data capture will result in an approximate one-quarter reduction in data management personnel and clinical research associates by January 2004
You may also be interested in...
AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix
AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix
Novartis R&D Portfolio Grows 44% Since 2000; Half Of Projects Are NMEs
Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York